Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression

Journal of Neuro-Oncology

Volumn 117, Issue 1, 2014, Pages 147-152

  McNamara, Mairéad G ^a   Lwin, Zarnie ^b   Jiang, Haiyan ^a   Templeton, Arnoud J ^a   Zadeh, Gelareh ^c   Bernstein, Mark ^c   Chung, Caroline ^a   Millar, Barbara Ann ^a   Laperriere, Normand ^a   Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Glioblastoma; Neutrophil lymphocyte ratio; Prognosis; Second surgery; Temozolomide; Time to first progression

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; REOPERATION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TIME TO FIRST PROGRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 84901642892     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1366-9     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Ammirati M, Galicich JH, Arbit E, Liao Y (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607-614
3. Barker FG, Chang SM, Gutin PH, et al. (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709-720
4. Dirks GR, Bernstein M, Muller PJ, Tucker WS (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271-275
5. Harsh GR, Levin VA, Gutin PH, et al. (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:615-621
6. Proctor MJ, Morrison DS, Talwar D, et al. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47:2633-2641
7. Templeton AJ, McNamara MG, Vera-Badillo, et al. (2013) Prognostic role of neutrophil to lymphocyte ratio (nlr) in solid tumors: a systematic review and meta-analysis. Eur J Cancer 47: (Suppl 1, abstract 1008)
8. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218-230
9. Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134:230-234
10. El-Hag A, Clark RA (1987) Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 139:2406-2413
11. McCourt M, Wang JH, Sookhai S, Redmond HP (1999) Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 134:1325-1331
12. Di Carlo E, Forni G, Musiani P (2003) Neutrophils in the antitumoral immune response. Chem Immunol Allergy 83:182-203
13. McCourt M, Wang JH, Sookhai S, Redmond HP (2001) Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol 27:396-403
14. Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J (2001) TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 49:63-69
15. Schaider H, Oka M, Bogenrieder T, et al. (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103:335-343
16. Shamamian P, Schwartz JD, Pocock BJ, et al. (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189:197-206
17. Scapini P, Nesi L, Morini M, et al. (2002) Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 168:5798-5804
18. Bambury RM, Teo MY, Power DG, et al. (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114:149-154
19. Polley MY, Lamborn KR, Chang SM, et al. (2010) Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 12:274-282
20. Hosmer DW, Lemeshow S, May S (2008) Applied survival analysis: regression modeling of time to event data. Wiley, New York
21. Gondo T, Nakashima J, Ohno Y, et al. (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085-1091
22. Helseth R, Helseth E, Johannesen TB, et al. (2010) Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 122:159-167
23. Terasaki M, Ogo E, Fukushima S, et al. (2007) Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. Surg Neurol 68:250-254
24. Yovino S, Grossman SA (2012) Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol 1:149-154
25. Cedres S, Torrejon D, Martinez A, et al. (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14:864-869
26. Kao SC, Pavlakis N, Harvie R, et al. (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805-5813
27. Brandes AA, Franceschi E, Tosoni A, et al. (2010) O6-Methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12:283-288
28. Park JK, Hodges T, Arko L, et al. (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838-3843
29. Grossman SA, Ye X, Lesser G, et al. (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473-5480
30. Carro MS, Lim WK, Alvarez MJ, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-325